Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data

Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone and factors ass...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2023-02, Vol.18 (2), p.e0281295-e0281295
Hauptverfasser:	Kim, Jiwon, Chung, Chiwook, Cho, Hyo Sin, Kim, Ho Cheol
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Age groups Aged Anorexia Anti-Inflammatory Agents, Non-Steroidal - adverse effects Biology and Life Sciences Body mass Body mass index Body size Carbon monoxide Care and treatment Comparative analysis Diffusion rate Drug dosages Drug Tapering Drug therapy Emphysema Fibrosis Humans Idiopathic Pulmonary Fibrosis Lung diseases Medical research Medicine and Health Sciences Medicine, Experimental Patient outcomes Patients Pulmonary fibrosis Pulmonary functions Pulmonary hypertension Pyridones - adverse effects Reduction Regression analysis Research and Analysis Methods Respiratory function Retrospective Studies Skin Smoking Statistical analysis Treatment Outcome Urticaria Variables Vital Capacity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!